Cognition Therapeutics (CGTX) EBT (2020 - 2026)

Cognition Therapeutics (CGTX) has reported EBT for 7 consecutive years, with -$7.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 44.63% year-over-year to -$7.7 million in Q2 2026; TTM through Jun 2026 was -$36.6 million, a 30.86% increase from a year earlier, with the FY2025 full-year figure at -$47.8 million, down 40.74% from the prior year.
• EBT was -$7.7 million for Q2 2026 at Cognition Therapeutics, up from -$8.8 million in the prior quarter.
• Over five years, EBT peaked at -$3.7 million in Q1 2022 and troughed at -$15.2 million in Q4 2023.
• A 5-year average of -$10.8 million and a median of -$12.4 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT slumped 1765.02% in 2022 and jumped 55.93% in 2025, its largest moves.
• Over 5 years, EBT stood at -$12.2 million in 2022, then declined by 24.44% to -$15.2 million in 2023, then advanced by 29.41% to -$10.7 million in 2024, then decreased by 27.48% to -$13.7 million in 2025, then surged by 43.4% to -$7.7 million in 2026.
• The last three EBT figures came in at -$7.7 million (Q2 2026), -$8.8 million (Q1 2026), and -$13.7 million (Q4 2025), per Business Quant data.